US › Healthcare

Belite Bio Inc ADR (BLTE)

US · Healthcare · Biotechnology

$170.35+0.67%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-28.4M

EPS

$-0.70

EPS estimate

$-0.73

EPS came in at -0.70 against a street estimate of -0.73 — a beat of 4.1%.

Key statistics

Market cap

$7.38B

Forward P/E

476.2

P/B

10.03

Book value

$19.29

EPS (TTM)

$-2.74

52-week high

$200.00

52-week low

$64.80

50-day MA

$159.67

200-day MA

$158.55

Beta

-1.24

Analyst view

Analysts rate Belite Bio Inc ADR a strong buy (5 buy, 0 hold, 0 sell out of 5) with an average price target of $227.33.

Shareholding

Insiders

44.06%

Institutions

24.29%

Largest institutional holders

Fund	Stake
Darwin Global Management, Ltd.	7.64%
Paradigm Biocapital Advisors LP	3.06%
UBS Group AG	1.91%
RTW INVESTMENTS, LLC	1.78%
Millennium Management LLC	1.23%
Holocene Advisors, LP	1.23%
Eventide Asset Management, LLC	0.97%
Deerfield Management Co	0.75%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Belite Bio Inc ADR — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.